Home  /  Resource Library  /  Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received >2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received >2 Prior Therapies: Updated Results from a Pivotal Phase II Study

ASH 2022